AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
Phase 1
Completed
- Conditions
- Ovarian NeoplasmsBRCA1 ProteinBRCA2 Protein
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT00516373
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
Phase 1
Completed
- Conditions
- Malignant Solid Tumors
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)Drug: Topotecan
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00516438
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT00516048
- Locations
- 🇰🇷
Research Site, Suwon City, Korea, Republic of
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic Neoplasms
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)Drug: Gemcitabine
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 68
- Registration Number
- NCT00515866
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00516074
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
Be SMART NIS, Moderate to Servere Asthma Patient Observation
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT00514787
- Locations
- 🇦🇹
Research Site, Vienna, Austria
Phase II Efficacy Study of AZD6244 in Colorectal Cancer
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00514761
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2012-08-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 241
- Registration Number
- NCT00509028
- Locations
- 🇯🇵
Research Site, Takizawa, Iwate, Japan
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5137
- Registration Number
- NCT00505388
- Locations
- 🇬🇧
Research Site, Welingborough, United Kingdom
Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2011-08-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT00504062
- Locations
- 🇯🇵
Research Site, Takizawa, Iwate, Japan
© Copyright 2025. All Rights Reserved by MedPath